The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...
Turkey tail: can it really support cancer treatment? - This functional mushroom has experts buzzing for its potential effects ...
Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...
James analyst Gary Nachman maintained an Outperform rating on AbbVie stock (NYSE:ABBV) with a $218.00 price target. The ...
A recent study published in the journal Medicine has found a possible connection between low vitamin D levels and increased ...
A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...
Wrist-worn devices can predict imminent inflammatory and symptomatic inflammatory bowel disease flare-ups as far in advance ...
For people who study the opioid epidemic, 2025 marks a grim anniversary: It has been 30 years since the Food and Drug Administration approved the opioid OxyContin for the treatment of chronic pain.
Multidisciplinary care is needed to ensure positive maternal and fetal health outcomes, especially in complex or high-risk ...
Overall, the use of 5-aminosalicylic acid (5-ASA) in combination with ustekinumab (UST) did not provide a significant benefit in patients with inflammatory bowel disease (IBD). Evidence Rating Level: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback